PeptideStack
5.2kquestions
20kanswers
220users

Is ATTAIN-1 a fair comparison of ecnoglutide against its comparator arm?

Asked 31 Jul 2024Modified 2.0 years agoViewed 34k times
28

For reference: ATTAIN-1 · ecnoglutide.

I would like to know whether this claim survives contact with evidence.

If the answer is "nobody has tested that", I would like that stated so I can stop looking.

What would count as evidence here, and does it exist?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
NA
askednoor_alhassan15k2831 Jul 2024
5Is there a reason to prefer the second method over the first, other than cost? – liam_bracken 28 days ago
add a comment

No answers yet

This question has not been answered. It has been viewed 34k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.